PVRL2

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

Retrieved on: 
Monday, November 6, 2023
Neoplasm, PVRL2, Ovarian cancer, Nivolumab, TIGIT, Pembrolizumab, Compugen, Telephone, Children's Art Project at The University of Texas MD Anderson Cancer Center, PD-1, Data, SITC, Immunotherapy, MD Anderson Cancer Center, Biology, Breast cancer, Annual general meeting, Platinum, TASE, Tumor microenvironment, University, Safety, Society, Patient, Birth control, Medical imaging, PVRIG

The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.

Key Points: 
  • The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.
  • "We were delighted to present at SITC clinical data which reinforces data previously presented, suggesting that COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy", said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • In addition, we presented data in metastatic breast cancer, another indication in which patients who typically do not respond to immunotherapy, derived clinical benefit from COM701 combinations."
  • I look forward to the results of the ongoing proof-of-concept study evaluating the combination of COM701, COM902 and pembrolizumab in platinum resistant ovarian cancer patients."

Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific

Retrieved on: 
Wednesday, November 16, 2022
Securities Act of 1933, SEC, U.S. Securities and Exchange Commission, Security (finance), Bispecific monoclonal antibody, Immunotherapy, Therapy, Compugen, Forward-looking statement, PVRIG, Risk, TIGIT, AstraZeneca, Company, Nasdaq, Terminology, Compugen (Israeli company), Research, Securities Exchange Act of 1934, Annual report, FC, Private Securities Litigation Reform Act, PVRL2, COVID-19, NASDAQ, TEL, Antibody, ClinicalTrials.gov, Fine chemical, Pharmaceutical industry, Bayer

"Like COM902, AZD2936 was engineered to reduce Fc effector functionality, with the potential to enhance anti-tumor activity.

Key Points: 
  • "Like COM902, AZD2936 was engineered to reduce Fc effector functionality, with the potential to enhance anti-tumor activity.
  • We believe that this is the optimal design and look forward to seeing how it plays out in the clinic."
  • Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients

Retrieved on: 
Monday, November 7, 2022
Private Securities Litigation Reform Act, Tumor microenvironment, Drug discovery, Ovarian cancer, FDA, Compugen, Population, Securities Exchange Act of 1934, Research, Annual report, U.S. Securities and Exchange Commission, ET, SEC, SITC, Company, Journal, B cell, Immunotherapy, Securities Act of 1933, Forward-looking statement, TLS, Security (finance), Society, Patient, Cancer, TIGIT, SVP, Nivolumab, DC, PVRL2, Neoplasm, Terminology, COVID-19, AstraZeneca, Society for Immunotherapy of Cancer, Risk, JITC, Q3, Compugen (Israeli company), Safety, TME, Poster, Nasdaq, Countersurveillance, TEL, Platinum, Bispecific monoclonal antibody, PD-1, NASDAQ, Drug Quality and Security Act, Vaccine, Pharmaceutical industry, Bayer, PVRIG

In addition to the data in the abstract, the Friday oral presentation will include new translational data from a number of platinum resistant ovarian cancer patients treated with COM701 monotherapy and from the fully enrolled MSS-CRC COM701 and nivolumab cohort.

Key Points: 
  • In addition to the data in the abstract, the Friday oral presentation will include new translational data from a number of platinum resistant ovarian cancer patients treated with COM701 monotherapy and from the fully enrolled MSS-CRC COM701 and nivolumab cohort.
  • "I believe the data we will present at SITC support the potential of PVRIG to open new possibilities in cancer immunotherapy," said Dr. Eran Ophir.
  • "The translational data are exciting because they support the anti-tumor activity we have shown with COM701 in combination with nivolumab in patients with MSS-CRC typically not responsive to approved checkpoint inhibitors.
  • Peripheral immune modulation was also seen with COM701 alone in a platinum resistant ovarian cancer patient with a partial response."

Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan

Retrieved on: 
Wednesday, August 24, 2022
AstraZeneca, Compugen (Israeli company), Security (finance), COVID-19, Research, Compugen, Securities Exchange Act of 1934, Securities Act of 1933, Tumor microenvironment, PVRL2, Private Securities Litigation Reform Act, Risk, Forward-looking statement, SEC, U.S. Securities and Exchange Commission, Patent, PD-1, Japan Patent Office, Nasdaq, Company, Immunotherapy, Bispecific monoclonal antibody, TIGIT, Terminology, Annual report, Method, TEL, Patient, Pharmaceutical industry, Bayer, PVRIG

2017-562952, titled "Anti-PVRIG antibodies and Methods of Use" augments previously issued patents by expanding and protecting COM701 beyond Europe and the U.S. to include coverage in Japan.

Key Points: 
  • 2017-562952, titled "Anti-PVRIG antibodies and Methods of Use" augments previously issued patents by expanding and protecting COM701 beyond Europe and the U.S. to include coverage in Japan.
  • COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.
  • Forward-looking statements include, but are not limited to, statements regarding the expected expiration date of the patent inJapan.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio

Retrieved on: 
Monday, August 8, 2022
Compugen, European Patent Convention, TIGIT, Securities Act of 1933, U.S. Securities and Exchange Commission, Forward-looking statement, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, SEC, Cancer, Terminology, NK, European Patent Office, PD-1, Patent, Security (finance), Research, Annual report, Patient, COVID-19, Company, Tumor microenvironment, PVRL2, Bispecific monoclonal antibody, NASDAQ, Risk, Method, Immunotherapy, Nasdaq, AstraZeneca, TEL, Compugen (Israeli company), Pharmaceutical industry, Vaccine, Bayer, PVRIG

COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.

Key Points: 
  • COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.
  • Compugen has identified PVRIG and TIGIT as key parallel and complementary inhibitory pathways in the DNAM-1 axis, which also intersect with the well-established PD-1 pathway.
  • Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

Retrieved on: 
Tuesday, January 18, 2022
Securities Exchange Act of 1934, United States patent law, Compugen, Research, Patient, Forward-looking statement, Bispecific monoclonal antibody, Private Securities Litigation Reform Act, Compugen (Israeli company), TIGIT, SEC, PVRL2, COVID-19, Risk, TEL, Standard of care, U.S. Securities and Exchange Commission, Nasdaq, AstraZeneca, USPTO, Patent, Tumor microenvironment, Therapy, Cancer, Neoplasm, Annual report, Immunotherapy, Security (finance), Securities Act of 1933, PD-1, Terminology, Pharmaceutical industry, Vaccine, PVRIG, Bayer

HOLON, Israel, Jan. 18, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ-GM: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted Compugen a new patent covering method of use for COM701, Compugen's potential first-in-class therapeutic antibody targeting PVRIG, or back-up anti-PVRIG antibody, in triple combination with any anti-PD-1 and any anti-TIGIT antibody for the treatment of cancer.

Key Points: 
  • 11,225,523 titled "Triple Combination Antibody Therapies" augments previously issued patents by expanding and protecting the use of COM701 for treating cancer patients, to include the triplet combination of COM701 with any anti-PD-1 antibody and any anti-TIGIT antibody.
  • "We are focused on maintaining our first mover advantage in the clinic, as the only company with monotherapy, doublet and triplet combination clinical studies evaluating PVRIG, TIGIT, and PD-1.
  • Forward-looking statements include, but are not limited to, statements regarding the expected expiration date of the patent inthe United States.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902

Retrieved on: 
Monday, October 4, 2021
Compugen, Securities Act of 1933, PVRL2, PVRIG, Compugen (Israeli company), Hope, Risk, TIGIT, Annual report, Security (finance), Therapy, Drug Quality and Security Act, NASDAQ, Private Securities Litigation Reform Act, Bispecific monoclonal antibody, U.S. Securities and Exchange Commission, Patient, Company, Antibody, Terminology, LSE, COVID-19, ClinicalTrials.gov, Research, Forward-looking statement, Securities Exchange Act of 1934, Nasdaq, TEL, SEC, Pharmaceutical industry

"We are proud that AstraZeneca's TIGIT bispecific program, derived from COM902, has advanced to the clinic and become our fourth clinical stage program originating from our innovative pipeline" said Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen.

Key Points: 
  • "We are proud that AstraZeneca's TIGIT bispecific program, derived from COM902, has advanced to the clinic and become our fourth clinical stage program originating from our innovative pipeline" said Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen.
  • In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen's monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT.
  • If additional products are developed based on Compugen's monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.